Exercise over pills: new study tests if moving more can shrink fatty liver

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient aged 18 and over * Affiliated with social security * Signature of informed consent * Diagnosis of NAFLD characterized by the presence of ultrasound steatosis, with a diagnosis made by a physician after a clinical and paraclinical examination as is usually done in routine care and having eliminated another cause of chronic liver disease. * Effective contraception system for women of childbearing age, a urine pregnancy test will be offered to these women as part of the assessment of the screening visit. Exclusion Criteria: * Patient under legal protection * Refusal to participate in the study * Alcohol consumption ≥ 30 g/d for men or ≥ 20 g/d for women * Presence of chronic liver disease from causes other than NAFLDs * Inability to obtain 10 valid measurements when performing a FibroScan liver elasticity measurement or continuous CAP® steatosis assessment during initial evaluation. * FibroScan ≥ 20 kPa at initial assessment * Presence or history of advanced chronic liver disease (cirrhosis) decompensated (Child A6, B or C). * Known history of a complication related to portal hypertension (including digestive haemorrhage related to portal hypertension, ascites or pleural effusion of cirrhotic cirrhosis, port-pulmonary hypertension). * Notion of type 2 diabetes unbalanced with an HbA1c ≥ 9%, less than 3 months (measurement of HbA1c is not required before signing the consent form). * Platelets \< 150000/mm3, within the previous 6 months. * Type 1 diabetes * Weight loss ≥ 10% of usual body weight, in the 6 months prior to inclusion * Introduction or dose modification of a GLP1 or orlistat agonist treatment \< 1 year * Practice of regular and/or intense physical activity, weekly (more than 3 hours per week) * Patients with solid organ or bone marrow transplants * Patient participating in another study evaluating a therapy to improve non-alcoholic fatty liver disease (NAFLD) * Contraindication to carrying out APA: * Absolute contraindication criteria: Any unstable pathology affecting a vital organ in particular cardiovascular or pulmonary. Unstable means any situation in which the absence of urgent therapeutic intervention could lead to the death of the patient. o Contraindication to physical activity Unstable acute coronary syndrome Decompensated heart failure Severe, uncontrolled ventricular rhythm disturbances Presence of an intracardiac thrombus with high embolic risk Presence of a medium to large pericardial effusion Recent history (\<6 months) of thrombophlebitis with or without pulmonary embolism Severe and/or symptomatic left ventricular ejection obstruction Any progressive inflammatory and/or infectious disease Severe pulmonary arterial hypertension